| Time | Topic | Speaker(s) |
|---|---|---|
| 07:00 PM | Welcome and Introductions | |
| 07:10 PM | Gender differences in CV risk factors, disease and management Learning Objectives Recognize sex-related differences in cardiovascular risk, presentation, and treatment outcomes to improve prevention and management. |
TBC |
| 07:30 PM | Workup and treatment of resistant hypertension Learning Objectives Identify patients with resistant hypertension and evaluate the role of the aldosterone pathway and emerging targeted therapies. |
TBC |
| 07:50 PM | Are we under-treating chronic kidney disease?
Learning Objectives Recognize chronic kidney disease in patients at cardiovascular risk and apply evidence-based therapies that reduce cardiovascular events and slow disease progression |
TBC |
| 08:10 PM | HFpEF diagnosis and managment in primary care Learning Objectives Recognize HFpEF in primary care and apply current diagnostic strategies and therapies that improve patient outcomes |
TBC |
| 08:30 PM | Q&A | |
| 09:00 PM | Closing Comments |
| Time | Topic | Speaker(s) |
|---|---|---|
| 07:00 PM | Welcome and Introductions | |
| 07:10 PM | Detection and management of ATTR in primary care Learning Objectives Identify clinical features that should prompt evaluation for transthyretin amyloidosis and initiate appropriate referral and management pathways |
TBC |
| 07:30 PM | What you need to know about metabolic dysfunction-associated steatotic liver Learning Objectives Recognize the link between MASLD and cardiovascular risk and apply cardiometabolic risk-reduction strategies |
TBC |
| 07:50 PM | GLP-1 therapies: applications in cardiovascular disease Learning Objectives Apply cardiovascular outcomes evidence for GLP-1 receptor agonists to reduce cardiovascular risk in patients with obesity or cardiometabolic disease |
Milan Gupta |
| 08:10 PM | New frontiers: Will CV inflammation be a treatment target? Learning Objectives Evaluate emerging evidence linking inflammation to cardiovascular disease and its potential implications for future patient care |
TBC |
| 08:30 PM | Q&A | |
| 09:00 PM | Closing Comments |
| Time | Topic | Speaker(s) |
|---|---|---|
| 07:00 PM | Welcome and Introductions | |
| 07:10 PM | Where does bempedoic acid fit in my practice? Learning Objectives Apply recent evidence to determine when bempedoic acid should be added to lipid-lowering therapy |
Liam Brunham |
| 07:30 PM | Prompt LDL-reduction post-MI: applying new guidelines to clinical practice Learning Objectives Apply current guideline recommendations to achieve rapid and sustained LDL-C reduction following myocardial infarction |
TBC |
| 07:50 PM | New frontiers: Where will oral PCSK9 inhibitors fit in clinical practice Learning Objectives Evaluate emerging evidence for oral PCSK9-targeting therapies and their potential role in lipid management |
Milan Gupta |
| 08:10 PM | New frontiers: Will Lp(a) be a treatment target? Learning Objectives Recognize the role of lipoprotein(a) in cardiovascular risk and evaluate emerging therapies targeting Lp(a) |
TBC |
| 08:30 PM | Q&A | |
| 09:00 PM | Closing Comments |
